Aytu BioScience 55336VAG5 Bond
AYTU Stock | USD 1.38 0.04 2.99% |
Aytu BioScience holds a debt-to-equity ratio of 0.474. At this time, Aytu BioScience's Short and Long Term Debt is comparatively stable compared to the past year. Interest Debt Per Share is likely to gain to 8,504 in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 8.1 M in 2024. . Aytu BioScience's financial risk is the risk to Aytu BioScience stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Aytu BioScience's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Aytu BioScience's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Aytu Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Aytu BioScience's stakeholders.
For most companies, including Aytu BioScience, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Aytu BioScience, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Aytu BioScience's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.2866 | Book Value 4.64 | Operating Margin (0.04) | Profit Margin (0.20) | Return On Assets (0.01) |
Aytu |
Given the importance of Aytu BioScience's capital structure, the first step in the capital decision process is for the management of Aytu BioScience to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Aytu BioScience to issue bonds at a reasonable cost.
Popular Name | Aytu BioScience MPLX LP 4875 |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US0547548745 |
Bond Issue ISIN Code | US55336VAG59 |
S&P Rating | Others |
Maturity Date | 1st of December 2024 |
Issuance Date | 1st of June 2016 |
Coupon | 4.875 % |
Aytu BioScience Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details |
Understaning Aytu BioScience Use of Financial Leverage
Aytu BioScience's financial leverage ratio measures its total debt position, including all of its outstanding liabilities, and compares it to Aytu BioScience's current equity. If creditors own a majority of Aytu BioScience's assets, the company is considered highly leveraged. Understanding the composition and structure of Aytu BioScience's outstanding bonds gives an idea of how risky it is and if it is worth investing in.
Last Reported | Projected for Next Year | ||
Short and Long Term Debt Total | 15.1 M | 8.1 M | |
Net Debt | -4.9 M | -5.1 M | |
Short Term Debt | 4.3 M | 3.6 M | |
Long Term Debt | 10.9 M | 9.4 M | |
Short and Long Term Debt | 4.3 M | 5.5 M | |
Long Term Debt Total | 10.1 M | 8.9 M | |
Net Debt To EBITDA | 4.82 | (37.19) | |
Debt To Equity | 0.55 | 0.01 | |
Interest Debt Per Share | 3.60 | 8,504 | |
Long Term Debt To Capitalization | 0.28 | 0.16 | |
Total Debt To Capitalization | 0.35 | 0.01 | |
Debt Equity Ratio | 0.55 | 0.01 | |
Cash Flow To Debt Ratio | (0.09) | (177.57) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.